Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OTX-TKI

Small molecule · Inhibitor · developed by Ocular Therapeutix

Phase 3 Most advanced trial
OCUL Developer
2 Registered trials

What is OTX-TKI?

OTX-TKI is an intravitreal axitinib implant, axitinib being a tyrosine kinase inhibitor. It is being studied in neovascular age-related macular degeneration.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Inhibitor
Pathways
angiogenesis
Therapy area
Ophthalmology
Developer
Ocular Therapeutix, Inc. (OCUL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06495918 Phase 3 Neovascular Age-related Macular Degeneration Active not recruiting OCUL
NCT06223958 Phase 3 Neovascular Age-Related Macular Degeneration Active not recruiting OCUL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neovascular Age-Related Macular Degeneration

More from Ocular Therapeutix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OCUL page.

Follow OCUL, the company behind OTX-TKI

See OCUL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCUL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.